Cognitive Function and Quality of Life in Interferon Therapy for Melanoma

Catherine M. Bender, Joyce M. Yasko, John M. Kirkwood, Christopher Ryan, Jacqueline Dunbar-Jacob and Thomas Zullo
Additional contact information
Thomas Zullo: University of Pittsburgh

Clinical Nursing Research, 2000, vol. 9, issue 3, 352-363

Abstract: The purpose of this pilot study was to describe short and long-term changes in cognitive function and quality of life in patients with melanoma receiving interferon (IFN) -2b. This study used a three-group, repeated measures design in which cognitive function and quality of life were evaluated prior to initiation of treatment at 3-month intervals during treatment and 3 months following the completion of treatment. The sample consisted of 16 adults with Stage II or III melanoma, randomized to one of three treatment groups. Participants in Arm A received high-dose IFN -2b, those in Arm B received low-dose IFN • -2b, and those in Arm C received no therapy (control). No significant changes in cognitive function were detected. In participants in ArmA, there was a significant deterioration in the physical well-being dimension of quality of life from baseline to 3 months after beginning therapy .

Date: 2000
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/10547730022158537 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:clnure:v:9:y:2000:i:3:p:352-363

DOI: 10.1177/10547730022158537

Access Statistics for this article

More articles in Clinical Nursing Research
Bibliographic data for series maintained by SAGE Publications ().